Application of antisense DNA method for the study of molecular bases of brain function and behavior

Behavior Genetics

Volumn 26, Issue 3, 1996, Pages 279-292

  Ogawa, Sonoko ^a   Pfaff, Donald W ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

analgesia; Antisense oligodeoxynucleotides; brain development; c fos mRNA; drinking; feeding; learning; locomotor activity; lordosis; mouse; progesterone receptor mRNA; rat; reproductive behavior; rotational behavior

Indexed keywords

COMPLEMENTARY DNA;

BEHAVIOR; BRAIN DEVELOPMENT; BRAIN FUNCTION; DRINKING; FEEDING; GENE EXPRESSION; LOCOMOTION; MOLECULAR GENETICS; MOUSE; NONHUMAN; RAT; REPRODUCTION; REVIEW;

ANIMALS; APPETITIVE BEHAVIOR; BEHAVIOR, ANIMAL; BRAIN; BRAIN MAPPING; DNA, ANTISENSE; GENE EXPRESSION; GENETICS, BEHAVIORAL; HUMANS; MICE; MOTOR ACTIVITY; NEUROSECRETORY SYSTEMS; PAIN THRESHOLD; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SEXUAL BEHAVIOR, ANIMAL; STEREOTYPED BEHAVIOR;

EID: 0030056448     PISSN: 00018244     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02359384     Document Type: Review

References (98)

1. Agrawal, S., Temsamani, J., and Tang, J. Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88:7595-7599.
2. Akabayashi, A., Wahlestedt, C., Alexander, J. T., and Leibowitz, S. F. (1994). Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Mol. Brain Res. 21:55-61.
3. Akhtar, S., Basu, S., Wickstrom, E., and Juliano, R. L. (1991a). Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res. 19:5551-5559.
4. Akhtar, S., Kole, R., and Juliano, R. L. (1991b). Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1793-1801.
5. Akhtar, S., Shoji, Y., and Juliano, R. L. (1992). Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides. Gene Regul. 1:133-143.
6. Amaratunga, A., Morin, P. J., Kosik, K. S., and Fine, R. E. (1993). Inhibition of kinesin synthesis and rapid anterograde axonal transport in vivo by an antisense oligonucleotide. J. Biol. Chem. 268:17427-17430.
7. Beaucage, S. L., and Iyer, R. P. (1993). The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 49:6123-6194.
8. Bennett, C. F., Chiang, M. Y., Chan, H. D., Shoemaker, J., and Mirabelli, C. K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033.
9. Blaustein, J. D., King, J. C., Toft, D. O., and Turcotte, J. (1988). Immunocytochemical localization of estrogen-induced progestin receptors in guinea pig brain. Brain Res. 474:1-15.
10. Boutorine, A. S., and Kostina, E. V. (1993). Reversible covalent attachment of cholesterol to oligodeoxyribonucleotides for studies of the mechanisms of their penetration into eucaryotic cells. Biochimie 75:35-41.
11. Capaccioli, S., Dipasquale, G., Mini, E., Mazzei, T., and Quattrone, A. (1993). Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun. 197:818-825.
12. Chiang, M. Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F., and Bennett, C. F. (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule-1 expression by two distinct mechanisms. J. Biol. Chem. 266:18162-18171.
13. Chiasson, B. J., Hooper, M. L., Murphy, P. R., and Robertson, H. A. (1992). Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. 227:451-453.
14. Chien, C. C., Brown, G., Pan, Y. X., and Pasternak, G. W. (1994). Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor. Eur. J. Pharmacol. 253:R7-R8.
15. Clarenc, J. P., Degols, G., Leonetti, J. P., Milhaud, P., and Lebleu, B. (1993). Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anti-Cancer Drug Des. 8:81-94.
16. Cook, P. D. (1991). Medicinal chemistry of antisense oligonucleotides - future opportunities. Anti-Cancer Drug Des. 6:585-607.
17. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. (1993). Disposition of the C-14-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1190.
18. Crooke, R. M. (1991). Invitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Des. 6:609-646.
19. Crooke, S. T. (1992). therapeutic applications of oligonucleotides. Biotechnology 10:882-886.
20. De Smidt, P. C., Doan, T. L., de Falco, S., and van Berkel, T. J. C. (1991). Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. 19:4695-4700.
21. Dragunow, M., Lawlor, P., Chiasson, B., and Robertson, H. (1993). c-fos antisense generates apomorphine and amphetamine-induced roration. Neuroreport 5:305-306.
22. Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C. J., Tsai, Y. J., Border, R., Ramsey, P., Martin, M., and Feigner, P. L. (1994). Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269:2550-2561.
23. Felgner, P. L., and Ringold, G. M. (1989). Cationic liposome-mediated transfection. Nature 337:387-388.
24. Felgner, P. L., Gadek, T. R., Holm, M., Roman, T., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987). Lipofectin: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84:7413-7417.
25. Ferreira, A., Niclas, J., Vale, R. D., Banker, G., and Kosik, K. S. (1992). Suppression of kinesin expression in cultured hippocampal neurons using antisense oligonucleotides. J. Cell Biol. 117:595-606.
26. Furdon, P. J., Dominski, Z., and Kole, R. (1989). RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate bonds. Nucleic Acids Res. 17:9193-9204.
27. Ghosh, M. K., Ghosh, K., and Cohen, J. S. (1993a). Phosphorothioate-phosphodiester oligonucleotide co-polymers - Assessment for antisense application. Anti-Cancer Drug Des. 8:15-32.
28. Ghosh, M. K., Ghosh, K., Dahl, O., and Cohen, J. S. (1993b). Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application. Nucleic Acids Res. 21:5761-5766.
29. Giles, R. V., Spiller, D. G., and Tidd, D. M. (1993). Chimeric oligodeoxynucleotide analogues - Enhanced cell uptake of structures which direct Ribonuclease-H with high specificity. Anti-Cancer Drug Des. 8:33-51.
30. Gryaznov, S. M., and Lloyd, D. H. (1993). Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions. Nucleic Acids Res. 21:5909-5915.
31. Gyurko, R., Wielbo, D., and Phillips, M. I. (1993). Antisense inhibition of at(1) receptor mrna and angiotensinogen mrna in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49: 167-174.
32. Harney, J. P., Scarbrough, K., Rosewill, K., and Wise, P. M. (1993). Effect of intracerebral infusion of VIP antisense oligonucleotides into the suprachiasmatic nuclei (SCN) on the LH surge in the rat. Soc. Neurosci. Abstr. 19:573.
33. Heilig, M., Engel, J. A., and Soderpalm, B. (1993). C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur. J. Pharmacol. 236:339-340.
34. Helene, C. (1991). The anti-gene strategy - Control of gene expression by triplex-forming-oligonucleotides. Anti-Cancer Drug Des. 6:569-584.
35. Iversen, P. (1991). Invivo studies with phosphorothioate oligonucleotides - Pharmacokinetics prologue. Anti-Cancer Drug Des. 6:531-538.
36. Jiao, S., Acsadi, G., Jani, A., Feigner, P. L., and Wolff, J. A. (1992). Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp. Neurol. 115:400-413.
37. Kaplitt, M. G., Pfaus, J. G., Kleopoulos, S. P., Hanlon, B. A., Rabkin, S. D., and Pfaff, D. W. (1991). Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2:320-330.
38. Kaplitt, M. G., Rabkin, S. D., and Pfaff, D. W. (1993). Molecular alternations in nerve cells: Direct manipulation and physiological mediation. Curr. Topics Neuroendocrinol. 11:169-191.
39. Khan, I. M., and Coulson, J. M. (1993). A novel method to stabilise antisense oligonucleotides against exonuclease degradation. Nucleic Acids Res. 21:2957-2958.
40. Lai, J., Bilsky, E. J., Rothman, R. B., and Porreca, F. (1994). Treatment with antisense oligodeoxynucleotide to the opioid δ receptor selectively inhibits δ2-agonist antinociception. Neuroreport 5:1049-1052.
41. Lauber, A. H., Romano, G. J., and Pfaff, D. W. (1991). Sex difference in estradiol regulation of progestin receptor mRNA in rat mediobasal hypothalamus as demonstrated by in situ hybridization. Neuroendocrinology 53:608-613.
42. LeGrand, G. C., Ramirez, J. J., Shih, Y.-H., Smith, T., Greenwood, R. S., Hayward, J. N., and Meeker, R. B. (1993). Antisense vasopressin oligonucleotides: Hypothalamic uptake, turnover and effects on fluid intake. Soc. Neurosci. Abstr. 19:92.
43. Leonetti, J. P., Mechti, N., Degols, G., Gagnor, C., and Lebleu, B. (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 88: 2702-2706.
44. Liebhaber, S. A., Russell, J. E., Cash, F. E., and Eshleman, S. S. (1992). Inhibition of messenger RNA translation by antisense sequences. Gene Regul. 1:163-174.
45. Lu, X. M., Fischman, A. J., Jyawook, S. L., Hendricks, K., Tompkins, R. G., and Yarmush, M. L. (1994). Antisense DNA delivery in vivo - Liver targeting by receptor-mediated uptake. J. Nucl. Med. 35:269-275.
46. Marshall, W. S., and Caruthers, M. H. (1993). Phosphorodithioate DNA as a potential therapeutic drug. Science 259: 1564-1569.
47. McCarthy, M. M., Malik, K. F., and Feder, H. H. (1990). Increased GABAergic transmission in medial hypothalamus facilitates lordosis but has the opposite effect in preoptic area. Brain Res. 507:40-44.
48. McCarthy, M. M., Pfaff, D. W., and Schwartz-Giblin, S. (1991). Activation of GABAa receptors in the midbrain central gray enhances and blockade reduces sexual behavior in the female rat. Exp. Brain Res. 86:108-116.
49. McCarthy, M. M., Brook, P. J., Pfaus, J. G., Brown, H. E., Flanagan, L. M., Schwarz-Giblin, S., and Pfaff, D. W. (1993a). Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 2:67-74.
50. McCarthy, M. M., Schlenker, E. H., and Pfaff, D. W. (1993b). Enduring consequences of neonatal treatment with antisense oligodeoxynucleotides to estrogen receptor messenger ribonucleic acid on sexual differentiation of rat brain. Endocrinology 133:433-439.
51. McCarthy, M. M., Masters, D. B., Rimvall, K., Schwartzgiblin, S., and Pfaff, D. W. (1994). Intracerebral administration of antisense oligodeoxynucleotides to GAD(65) and GAD(67) mRNAs modulate reproductive behavior in the female rat. Brain Res. 636:209-220.
52. Miller, P. S. (1991). Oligonucleotide methylphosphonates as antisense reagents. Biotechnology 9:358-362.
53. Miller, P. S. (1993). Antisense oligodeoxyribonucleoside methylphosphonates and their psoralen conjugates. Clin. Chem. 39:713-715.
54. Milligan, J. F., Matteucci, M. D., and Martin, J. C. (1993). Current concepts in antisense drug design. J. Med. Chem. 36:1923-1937.
55. Mirabelli, C. K., Bennett, C. F., Anderson, K., and Crooke, S. T. (1991). Invitro and invivo pharmacologic activities of antisense oligonucleotidcs. Anti-Cancer Drug Des. 6: 647-661.
56. Mitsushima, D., Marzban, F., Hei, D. L., Golos, T. G., and Terasawa, E. (1993). Direct infusion of a glutamic acid decarboxylase (GAD1) antisense oligonucleotide into the stalk-median eminence increases the in vivo LHRH release in prepubertal female monkeys. Soc. Neurosci. Abstr. 19:618.
57. Moguilewsky, M., and Raynaud, J.-P. (1979). The relevance of hypothalamic and hypophyseal progestin receptor regulation in the induction and inhibition of sexual behavior in the female rat. Endocrinology 105:516-522.
58. Neckers, L., and Whitesell, L. (1993). Antisense technology - Biological utility and practical considerations. Am. J. Physiol. 265:L1-L12.
59. Ogawa, S., Olazabal, U. E., and Pfaff, D. W. (1992). Behavioral changes after local administration of antisense sequence for progesterone receptor mRNA in female rat hypothalamus. In Baserga, R., and Denhardt, D. T. (eds.), Antisense Strategies, New York Academy of Sciences, New York, pp. 298-299.
60. Ogawa, S., Brown, H. E., and Pfaff, D. W. (1993). Effect of antisense DNA for progesterone receptor mRNA on progestin binding in mouse brain. Soc. Neurosci. Abstr. 19: 821.
61. Ogawa, S., Brown, H. E., Okano, H. J., and Pfaff, D. W. (1995). Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Reg. Pep. 59:143-149.
62. Ogawa, S., Olazabal, U. E., Parhar, I. S., and Pfaff, D. W. (1994). Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone receptor immunoreactivity in female rat. J. Neurosci. 14:1766-1774.
63. Osen-Sand, A., Catsicas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G., and Catsicas, S. (1993). Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature 364: 445-448.
64. Parsons, B., MacLusky, N. J., Krey, L., Pfaff, D. W., and McEwen, B. S. (1980). The temporal relationship between estrogen-inducible progestin receptors in the female rat brain and the time course of estrogen activation of mating behavior. Endocrinology 107:774-779.
65. Parsons, B., McEwen, B. S., and Pfaff, D. W. (1982a). A discontinuous schedule of estradiol treatment is sufficient to activate progesterone-facilitated feminine sexual behavior and to increase cytosol receptors for progestins in the hypothalamus of the rat. Endocrinology 110:613-624.
66. Parsons, B., Rainbow, T. C., MacLusky, N. J., and McEwen, B. S. (1982b). Progestin receptor levels in rat hypothalamic and limbic nuclei. J. Neurosci. 2:1446-1452.
67. Pfaff, D. W., Schwartzgiblin, S., McCarthy, M. M., and Kow, L. M. (1994) Cellular and molecular mechanisms of female reproductive behaviors. In Knobil, E., and Neill, J. D. (eds.), Physiology of Reproduction, Vols. 1 and 2, 2nd ed., Raven Press, New York, pp. 107-220.
68. Pollio, G., Xue, P., Zanisi, M., Nicolin, A., and Maggi, A. (1993). Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Mol. Brain Res. 19:135-139.
69. Romano, G. J., Krust, A., and Pfaff, D. W. (1989). Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: An in situ hybridization study. Mol. Endocrinol. 3:1295-1300.
70. Ropert, C., Malvy, C., and Couvreur, P. (1993). Inhibition of the friend retrovirus by antisense oligonucleotides encapsulated in liposomes - Mechanism of action. Pharm. Res. 10:1427-1433.
71. Sakai, R. R., He, P. F., Yang, X. D., Ma, L. Y., Guo, Y. F., Reilly, J. J., Moga, C. N., and Fluharty, S. J. (1994). Intracerebroventricular administration of at(1) receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62:2053-2056.
72. Schneider, W., Ramachandran, C., Satyawaroop, P. G., and Shyamala, G. (1991). Murine progesterone receptor exists predominantly as the 83-kilodalton "A" form. J. Steroid Biochem. 38:285-291.
73. Shaw, J.-P., Kent, K., Bird, J., Fishback, J., and Froehler, B. (1991). Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. 19:747-750.
74. Shoji, Y., Akhtar, S., Periasamy, A., Herman, B., and Juliano, R. L. (1991). Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19:5543-5550.
75. Shyamala, G., Schneider, W., and Schott, D. (1990). Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology 126:2882-2889.
76. Sommer, W., Bjelke, B., Ganten, D., and Fuxe, K. (1993). Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport 5:227-280.
77. Standifer, K. M., Chien, C. C., Wahlestedt, C., Brown, G. P., and Pasternak, G. W. (1994). Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron 12:805-810.
78. Stec, W. J., Grajkowski, A., Koziolkiewicz, M., and Uznanski, B. (1991). Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). Nucleic Acids Res. 19:5883-5888.
79. Stein, C. A. (1992). Anti-sense oligodeoxynucleotides - Promises and pitfalls. Leukemia 6:967-974.
80. Stein, C. A., Mori, K., Loke, S. L., Subasinghe, C., Shinozuka, K., Cohen, J. S., and Neckers, L. M. (1988). Phosphrothioate and normal oligodeoxyribonucleotide with 5′-linked acridine: Characterization and preliminary kinetics of cellular uptake. Gene 72:333-341.
81. Stein, C. A., Tonkinson, J. L., and Yakubov, L. (1991). Phosphorothioate oligodeoxynucleotides - Anti-sense inhibitors of gene expression. Pharmacol. Ther. 52:365-384.
82. Sueishi, T., Seki, T., Juni, K., Hasegawa, T., Saneyoshi, M., and Kawaguchi, T. (1994). Novel stabilizing method for antisense oligodeoxynucleotides. Pharm. Res. 11:455-457.
83. Thierry, A. R., and Dritschilo, A. (1992). Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acid Res. 20:5691-5698.
84. Thierry, A. R., Rahman, A., and Dritschilo, A. (1992). Liposomal delivery as a new approach to transport antisense oligonucleotides. Gene Regul. 1:147-161.
85. Uhlmann, E., and Peyman, A. (1990). Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. 90:544-584.
86. Wahlestedt, C. (1994). Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15:42-46.
87. Wahlestedt, C., Golanov, E., Yamamoto, S., Yee, F., Ericson, H., Yoo, H., Inturrisi, C. E., and Reis, D. J. (1993a). Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363:260-263.
88. Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F., and Heilig, M. (1993b). Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligonucleotides. Science 259: 528-531.
89. Warembourg, M., Logeat, R., and Milgrom, E. (1986). Immunocytochemical localization of progesterone receptor in the guinea pig central nervous system. Brain Res. 384: 121-131.
90. Weiss, B., Zhou, L. W., Zhang, S. P., and Qin, Z. H. (1993). Antisense oligodeoxynucleotide inhibits D(2)-dopamine receptor-mediated behavior and D(2)-messenger RNA. Neuroscience 55:607-612.
91. Whitesell, L., Geselowitz, D., Chavany, C., Fahmy, B., Walbridge, S., Alger, J. R., and Neckers, L. M. (1993). Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides - implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA 90:4665-4669.
92. Yu, C., Brussaard, A. B., Yang, X., Listerud, M., and Role, L. W. (1993). Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons. Dev. Genet. 14: 296-304.
93. Zendegui, J. G., Vasquez, K. M., Tinsley, J. H., Kessler, D. J., and Hogan, M. E. (1992). In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res. 20:307-314.
94. Zhang, M., and Creese, I. (1993). Antisense oligodeoxynucleotide reduces brain dopamine-D2 receptors - Behavioral correlates. Neurosci. Lett. 161:223-226.
95. Zhou, L. W., Zhang, S. P., Qin, Z. H., and Weiss, B. (1994). In vivo administration of an oligodeoxynucleotide antisense to the d-2 dopamine receptor messenger RNA inhibits d-2 dopamine receptor-mediated behavior and the expression of d-2 dopamine receptors in mouse striatum. J. Pharmacol. Exp. Ther. 268:1015-1023.
96. Zhu, N., Liggitt, D., Liu, Y., and Debs, R. (1993). Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211.
97. Zon, G. (1988). Oligonucleotide analogues as potential chemotherapeutic agents. Pharm. Res. 5:539-549.
98. Zon, G., and Geiser, T. G. (1991). Phosphorothioate oligonucleotides - Chemistry, purification, analysis, scale-up and future directions. Anti-Cancer Drug Des. 6:539-568.